Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells

Background: The relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Villamañan, Lucía, Martínez-Escardó, Laura, Arús, Carles, Yuste, Victor J., Candiota, Ana P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036897/
https://www.ncbi.nlm.nih.gov/pubmed/33810611
http://dx.doi.org/10.3390/ijms22073453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036897/
https://www.ncbi.nlm.nih.gov/pubmed/33810611
http://dx.doi.org/10.3390/ijms22073453

Ejemplares similares